Conduit Pharmaceuticals Statistics Share Statistics Conduit Pharmaceuticals has 2.93M
shares outstanding. The number of shares has increased by 0.31%
in one year.
Shares Outstanding 2.93M Shares Change (YoY) 0.31% Shares Change (QoQ) 0.31% Owned by Institutions (%) 0.09% Shares Floating 2.25M Failed to Deliver (FTD) Shares 37 FTD / Avg. Volume 0.01%
Short Selling Information The latest short interest is 39.42K, so 1.64% of the outstanding
shares have been sold short.
Short Interest 39.42K Short % of Shares Out 1.64% Short % of Float 1.78% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -11.76 and the forward
PE ratio is null.
Conduit Pharmaceuticals's PEG ratio is
-0.03.
PE Ratio -11.76 Forward PE n/a PS Ratio 0.23 Forward PS n/a PB Ratio -30.82 P/FCF Ratio -21.51 PEG Ratio -0.03
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Conduit Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.25,
with a Debt / Equity ratio of -1.1.
Current Ratio 0.25 Quick Ratio 0.25 Debt / Equity -1.1 Debt / EBITDA -0.47 Debt / FCF -0.77 Interest Coverage -10.24
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $153.7M Profits Per Employee $-2.97M Employee Count 6 Asset Turnover 219.94 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -99.33% in the
last 52 weeks. The beta is 1.91, so Conduit Pharmaceuticals's
price volatility has been higher than the market average.
Beta 1.91 52-Week Price Change -99.33% 50-Day Moving Average 2.39 200-Day Moving Average 50.35 Relative Strength Index (RSI) 31.6 Average Volume (20 Days) 357,516
Income Statement In the last 12 months, Conduit Pharmaceuticals had revenue of 922.22M
and earned -17.8M
in profits. Earnings per share was -20.53.
Revenue 922.22M Gross Profit -457K Operating Income -15.42M Net Income -17.8M EBITDA -15.84M EBIT -16.3M Earnings Per Share (EPS) -20.53
Full Income Statement Balance Sheet The company has 554K in cash and 7.46M in
debt, giving a net cash position of -6.9M.
Cash & Cash Equivalents 554K Total Debt 7.46M Net Cash -6.9M Retained Earnings -29.1M Total Assets 3.33B Working Capital 607.04M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -9.68M
and capital expenditures -51K, giving a free cash flow of -9.73M.
Operating Cash Flow -9.68M Capital Expenditures -51K Free Cash Flow -9.73M FCF Per Share -4.78
Full Cash Flow Statement Margins Gross margin is -0.05%, with operating and profit margins of -1.67% and -1.93%.
Gross Margin -0.05% Operating Margin -1.67% Pretax Margin -1.93% Profit Margin -1.93% EBITDA Margin -1.72% EBIT Margin -1.67% FCF Margin -1.06%
Dividends & Yields CDT does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for CDT.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on May 20, 2025. It was a
backward
split with a ratio of 1:15.
Last Split Date May 20, 2025 Split Type backward Split Ratio 1:15
Scores Altman Z-Score 1.22 Piotroski F-Score 7
